• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Delenex Therapeutics

edit

Delenex Therapeutics AG is a Swiss biotech company developing therapeutic antibody fragments targeting serious medical diseases with high unmet need. The company’s fragments are being designed for local/topical application by using the benefits of an antibody therapy with only limited systemic exposure. Its clinically validated technology delivers antibodies exhibiting the highest affinity, solubility and stability all combined with a very low risk of immunogenicity.

Recent Milestones

edit

• 
  Delenex Therapeutics received $19.3M in Series A funding. (5/3/11)
  Posted 5/3/11 at 6:04pm via finsmes.com
• 
  Delenex Therapeutics received $14M in Series A funding. (11/12/10)
  Posted 11/14/10 at 6:38pm via finsmes.com
• 
  Delenex Therapeutics added Thomas Hecht as Executive Chairman.
  Posted 11/14/10 at 6:38pm
• 
  Delenex Therapeutics added Eric de la Fortelle as CEO.
  Posted 2/1/11 at 10:32pm
• 
  Delenex Therapeutics added Jakob Schlapbach as CFO.
  Posted 2/1/11 at 10:32pm

Videos

Screenshots

edit

Sources

1. Delenex Therapeutics Closes CHF13.5M Series A Venture Capital Financing Round (finsmes.com) [edit]
2. Delenex Therapeutics Raises $19.3M (finsmes.com) [edit]